Results 91 to 100 of about 24,071 (243)

Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema [PDF]

International Journal of Ophthalmology
AIM: To investigate the efficacy of aflibercept combined with sub-tenon injection of triamcinolone acetonide (TA) in treating diabetic macular edema (DME) and to examine changes in growth factors and inflammatory mediator levels in aqueous humor after ...
De-Shuang Li, Hong-Xia Liao, Jing-Lin Zhang, Bo Qin   +3 more
doaj   +1 more source

Long-Term Effects of Aflibercept Injections on Lesion-Free Retina in Eyes with Neovascular Age-Related Macular Degeneration [PDF]

, 2023
Nur Demir, Belma Kayhan, Sukru Sevincli, Murat Sönmez   +3 more
openalex   +1 more source

Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists [PDF]

, 2014
Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors ...
Christophe Tournigand, Jean-Baptiste Rey, Vincent Launay-Vacher   +2 more
core   +1 more source

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj  

Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea®)

Ophthalmology and Therapy
Introduction SB15 is a proposed biosimilar product of reference aflibercept (Eylea®), an approved biological drug product for retinal diseases including neovascular age-related macular degeneration (nAMD).
Hangyeore Lee, Jongcheol Huh, Dayoung Kim, Soye Lee, Jaeil Lee, Jungmin Lee, Beom Chan Kim, Jinsu Song   +7 more
doaj   +1 more source

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration

BMJ Open Ophthalmology
Purpose Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD).
Siegfried Priglinger, Jakob Siedlecki, Benedikt Schworm, Franziska Eckardt, Michael Hafner, Ben Asani, Caspar Liesenhoff, Alexander Kufner, Johannes Benedikt Schiefelbein   +8 more
doaj   +1 more source

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks

Indian Journal of Ophthalmology, 2015
In this study, we reported the clinical results of switching from ranibizumab to aflibercept for the treatment of an insufficient responder with choroidal neovascularization (CNV) secondary to angioid streaks (AS).
Ebru Esen, Selçuk Sizmaz, Nihal Demircan   +2 more
doaj   +1 more source

Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and Aflibercept [PDF]

, 2021
Maria Vadalà, Massimo Castellucci, Giulia Guarrasi, Giovanni Cillino, Vincenza Bonfiglio, Alessandra Casuccio, Salvatore Cillino   +6 more
openalex   +1 more source

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. [PDF]

, 2016
BACKGROUND: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival.
Ball, A., Bowers, M., Bridgewater, J,A., Corkhill, A., Cunningham, D., Dixon, E., Falk, S., Finch-Jones, M., Garden, O.J., Hickish, Tamas F., Hornbuckle, J., Iveson, T., Maishman, T., Maughan, T.S., O'Reilly, D.A., Primrose, J.N., Pugh, S.A., Radford, M., Rees, C., Rees, M., Siriwardena, A.K., Stanton, L., Valle, J.W.   +22 more
core   +6 more sources

Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis

Ophthalmology and Therapy
Introduction This systematic review and meta-analysis aimed to provide an updated evidence base for clinical decision-making by comparing the efficacy and safety of aflibercept 2 mg and ranibizumab in treating retinal vein occlusion (RVO).
Jing Wu, Xiaoning He, Fang Qi, Zhan Zhao, Zhe Xu, Hong Yan   +5 more
doaj   +1 more source